elderly couple 300LEXINGTON, Ky. (12/8/13) – A new clinical trial being conducted at the University of Kentucky Sanders-Brown Center on Aging and the UK Alzheimer’s Disease Center may signal new hope in the future for those who might be afflicted with the devastating disease. Taking laboratory research pioneered at SBCoA and the associated UK ADC into human trials, the federally-funded research project will examine the therapeutic potential of microRNAs to delay or prevent Alzheimer’s disease.
 
Led by physician-scientist Dr. Gregory Jicha, and building off of the work of fellow SBCoA physician-scientist Dr. Peter Nelson, the project, formally titled “Modulation of micro-RNA pathways by gemfibrozil in pre-dementia Alzheimer disease,” will operate with a total budget of $1.5 million over three years. Funding was awarded by the National Institute on Aging as the result of a competitive process.
 
In 2006, the Nobel Prize was awarded for the discovery of microRNA biology. MicroRNAs are now understood by scientists to be implicated in health and disease states for hundreds of conditions. However, despite advances in microRNA technology, to date no group in the world has been able to apply microRNA discoveries in human clinical trials to affect neurodegenerative disease states.
 
“We are currently funded by the NIA/NIH and approved to take Dr. Pete Nelson's microRNA discoveries into the first-ever human clinical trial of microRNA modulation to influence a disease state. This trial is just starting, but it is not a hope or future expectation, it is real today,” said Jicha. “The microRNA project at the University of Kentucky is the first trial in the history of mankind to test the therapeutic potential of microRNAs in modulating neurodegenerative disease states. If our discovery is successful it will open the door for untold therapeutic developments for the diseases that plague us all as we age.”
 
As background, Jicha explained that, “Many have heard the speculation that more than 90 percent of our DNA is ‘junk’. The truth is that if we had ‘junk’, it would have been weeded out evolutionarily.”
 
In reality, at least some of this DNA codes for small fragments of RNA that regulate gene expression in health and disease states. These small RNA fragments are called microRNA. In previous work, Nelson of SBCoA has been able to show that one such microRNA is reduced in the brain very early as Alzheimer’s disease pathology begins.
 
“Nelson’s evidence suggests that if we can increase the levels of this microRNA, we may be able to prevent Alzheimer’s disease, or even stop it when it is in its earliest stages,” said Jicha.

Fortunately, a FDA-approved drug that can increase miRNA-107 levels already exists, and is currently approved for treating high cholesterol. In cell culture experiments this drug, called gemfibrozil, can prevent Alzheimer’s disease-associated changes.
 
Gemfibrozil is one of a class of drugs called fibrates, currently used worldwide to treat high cholesterol. Previous studies of people taking fibrates have consistently demonstrated an approximately 50 percent reduction in risk for Alzheimer’s disease.
 
“In U.S. terms,” said Jicha, “that could potentially cut the burden of Alzheimer’s from 5.4 million cases to 2.7 million nationwide.”
 
“This innovative clinical trial is a great example of the ‘bench to bedside’ focus of the UK Sanders-Brown Center on Aging – taking a research discovery made in the laboratory and translating that knowledge into a human clinical study. This pioneering clinical study testing the therapeutic potential of microRNAs to delay or prevent Alzheimer’s disease clearly shows how Pete Nelson and Greg Jicha, and the Sanders-Brown Center on Aging, are leading the world in testing promising new approaches to Alzheimer’s therapy,” said Linda Van Eldik, director of the Sanders-Brown Center on Aging.
 
Watch Dr. Jicha discuss the importance of clinical trials to Alzheimer's research below:

SurfKY News
Information provided by Allison Elliott-Shannon

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

Posted on 2/2/14
3/13 - 16
1 DOW 18,024.06
+183.54 (1.03%)    
2 S&P 2,108.29
+22.78 (1.09%)    
3 NASDAQ 5,005.39
+63.97 (1.29%)    
3/13 - 16

Most Read This Week

April 28, 2015 4026

Search for Stolen Vehicle Ends with Woman Charged…

by SurfKY News
April 27, 2015 3383

Online Petition Seeking Re­opening of Shanice…

by Samantha Carver, SurfKY News
April 28, 2015 3229

Man Charged with Stalking Smoke Shop Clerk

by MPD
April 27, 2015 2768

Hopkins County Drug War ― Are We Winning?

by Doreen Dennis, SurfKY News
April 30, 2015 2673

Family Says 'Goodbye' to Dog After It Allegedly…

by Doreen Dennis, SurfKY News

Most Read This Month

April 17, 2015 15183

An Open Letter from an Addict

by Olivia Kirks
April 23, 2015 8380

Man Charged with Sodomy, Incest/Victim under 12

by SurfKY News

Stories Trending Now

May 02, 2015 880

Frymire’s Life Accomplishments, Dedication to MCC…

by Tammy Holloway, SurfKY News
May 01, 2015 741

Above and Beyond: Leighann Stroud

by Gary Gates, SurfKY News
May 02, 2015 419

Don't Bet on Supreme Court Overturning Marriage…

by Richard Nelson
May 02, 2015 413

Homegrown by Heroes Receives Donation from…

by Ted Sloan
May 02, 2015 357

Weeknight activities the whole family can enjoy

by SurfKY News
May 02, 2015 356

New Mather Metals to Expand in Franklin

by Office of the Governor
May 02, 2015 336

Hooked on Science - 'Kentucky Derby Balloon Race'

by Jason Lindsey
May 02, 2015 291

Happenings, Meetings Listed for Following Week

by Amber Averitt, SurfKY News
May 02, 2015 251

Conquering the clutter: Cleanliness with kids is…

by SurfKY News